In addition, therapeutic targeting of NPC1 in MYC-driven HCC using AAV8-shNPC1 significantly reduced tumor size and number (Supplementary Fig. 9t–x), with knockdown efficiency validated by Western blotting (Supplementary Fig. 9y). This evidence concerns the gene NPC1 and hepatocellular carcinoma.